TY - JOUR
T1 - Frequent exacerbators--a distinct phenotype of severe asthma
AU - Kupczyk, M.
AU - ten Brinke, A.
AU - Sterk, P. J.
AU - Bel, E. H.
AU - Papi, A.
AU - Chanez, P.
AU - Nizankowska-Mogilnicka, E.
AU - Gjomarkaj, M.
AU - Gaga, M.
AU - Brusselle, G.
AU - Dahlén, B.
AU - Dahlén, S.-E.
AU - AUTHOR GROUP
AU - Weersink, Els
AU - Papadopoulos, Nikos
AU - Oikonomidou, Erasmia
AU - Zervas, Eleftherios
AU - Contoli, Marco
AU - Pauwels, Romain A.
AU - Joos, Guy F.
AU - de Rudder, Isabelle
AU - Schelfhout, Vanessa
AU - Richter, Kai
AU - Gerding, Daisy
AU - Magnussen, Helgo
AU - Siafakas, Nikos M.
AU - Tzortzaki, Eleni
AU - Samara, Katerina
AU - Plataki, Maria
AU - Papadopouli, Eva
AU - Szczeklik, Andrzej
AU - Ziolkowska-Graca, Bozena
AU - Kania, Aleksander
AU - Gawlewicz-Mroczka, Agnieszka
AU - Duplaga, Mariusz
AU - Figiel, Ewa
AU - Rabe, Klaus F.
AU - Hiemstra, Pieter S.
AU - Gauw, Stefanie
AU - van Veen, Ilonka
AU - Kips, Johan C.
AU - Johnston, Sebastian L.
AU - Mallia, Patrick
AU - Campbell, Deborah A.
AU - Robinson, Douglas S.
AU - Kanniess, Frank
AU - Fabbri, Leo M.
AU - Romagnoli, Micaela
AU - Vachier, Isabelle
AU - Devautour, Catherine
AU - Meziane, Lahouari
PY - 2014
Y1 - 2014
N2 - Exacerbations represent a major source of morbidity and mortality in asthma and are a prominent feature of poorly controlled, difficult-to-treat disease. The goal of our study was to provide a detailed characterization of the frequent exacerbator phenotype and to identify risk factors associated with frequent and seasonal exacerbations. Ninety-three severe asthmatics (SA) and 76 mild-to-moderate patients (MA) were screened and prospectively followed up for 1 year (NCT00555607). Medical history, baseline clinical data and biomarkers were used to assess risk factors for frequent exacerbations. During the study, 104 exacerbations were recorded in the SA group and 18 in the MA. Frequent exacerbators were characterized by use of higher doses of inhaled (1700 vs. 800 μg) and oral (6.7 vs. 1.7 mg) glucocorticosteroids, worse asthma control (ACQ score 2.3 vs. 1.4), lower quality of life (SGRQ score 48.5 vs. 33.3), higher sputum eosinophils (25.7% vs. 8.2%) and a more rapid decline in FEV1 /FVC ratio (-0.07 vs. -0.01 ΔFEV1 /FVC, frequent vs. non-frequent, respectively, P < 0.05). Exhaled NO > 45 p.p.b. and a history of smoking were associated with an increased risk of frequent exacerbations (odds ratios: 4.32 and 2.90 respectively). We were able to distinguish and characterize a subphenotype of asthma subjects--frequent exacerbators--who are significantly more prone to exacerbations. Patients with FeNO > 45 p.p.b. and a history of smoking are at increased risk of frequent exacerbations and require careful monitoring in clinical practice
AB - Exacerbations represent a major source of morbidity and mortality in asthma and are a prominent feature of poorly controlled, difficult-to-treat disease. The goal of our study was to provide a detailed characterization of the frequent exacerbator phenotype and to identify risk factors associated with frequent and seasonal exacerbations. Ninety-three severe asthmatics (SA) and 76 mild-to-moderate patients (MA) were screened and prospectively followed up for 1 year (NCT00555607). Medical history, baseline clinical data and biomarkers were used to assess risk factors for frequent exacerbations. During the study, 104 exacerbations were recorded in the SA group and 18 in the MA. Frequent exacerbators were characterized by use of higher doses of inhaled (1700 vs. 800 μg) and oral (6.7 vs. 1.7 mg) glucocorticosteroids, worse asthma control (ACQ score 2.3 vs. 1.4), lower quality of life (SGRQ score 48.5 vs. 33.3), higher sputum eosinophils (25.7% vs. 8.2%) and a more rapid decline in FEV1 /FVC ratio (-0.07 vs. -0.01 ΔFEV1 /FVC, frequent vs. non-frequent, respectively, P < 0.05). Exhaled NO > 45 p.p.b. and a history of smoking were associated with an increased risk of frequent exacerbations (odds ratios: 4.32 and 2.90 respectively). We were able to distinguish and characterize a subphenotype of asthma subjects--frequent exacerbators--who are significantly more prone to exacerbations. Patients with FeNO > 45 p.p.b. and a history of smoking are at increased risk of frequent exacerbations and require careful monitoring in clinical practice
U2 - 10.1111/cea.12179
DO - 10.1111/cea.12179
M3 - Article
C2 - 24447083
SN - 0954-7894
VL - 44
SP - 212
EP - 221
JO - Clinical and experimental allergy
JF - Clinical and experimental allergy
IS - 2
ER -